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A B S T R A C T
the present guidelines on the management of advanced non-small cell lung cancer 
(nsCLC) were formulated by the ELCWP in October 2006. they are designed to 
answer the following twelve questions: 1) What benefits can be expected from che-
motherapy and what are the treatment objectives? 2) What are the active chemothera-
peutic drugs for which efficacy has been shown? 3) Which are the most effective 
platinum-based regimens? 4) Which is the indicated dosage of cisplatin? 5) Can car-
boplatin be substituted for cisplatin? 6) Which is the optimal number of cycles to be 
administered? 7) Can non-platinum based regimens be substituted for platinum based 
chemotherapy as first-line treatment? 8) is there an indication for sequential chemo-
therapy? 9) What is the efficacy of salvage chemotherapy and which drugs should be 
used in that indication? 10) What is the place of targeted therapies? 11) What is the 
place of chemotherapy in the management of a patient with brain metastases? 12) 
Which specific drugs can be used for the patient with bone metastases?
I N T R O D U C T I O N
this is the third of a series of five articles, reporting clinical practice guidelines 
for lung cancer, formulated by the European Lung Cancer Working Party (ELCWP). 
the articles consecutively present the recommended treatment of early (resectable) 
stages of non-small cell lung cancer (nsCLC) [1], locoregionally advanced nsCLC 
[2], metastatic nsCLC and small-cell lung cancer (sCLC) of limited and extensive 
stage. the rational of the reasons and methodology used for those guidelines has been 
previously reported [1].
after an extensive discussion, a consensus was reached among members of the 
Group to formulate the guidelines of treatment of advanced stages of non-small lung 
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cancer on the basis of twelve predefined essential questions: 
1) What benefits can be expected from chemotherapy and 
what are the treatment objectives? 2) What are the active 
chemotherapeutic drugs for which efficacy has been shown? 
3) Which are the most effective platinum-based regimens? 4) 
Which is the indicated dosage of cisplatin? 5) Can carboplatin 
be substituted for cisplatin? 6) Which is the optimal number 
of cycles to be administered? 7) Can non-platinum based 
regimens be substituted for platinum based chemotherapy as 
first-line treatment? 8) is there an indication for sequential 
chemotherapy? 9) What is the efficacy of salvage chemo-
therapy and which drugs should be used in that indication? 
10) What is the place of targeted therapies? 11) What is the 
place of chemotherapy in the management of a patient with 
brain metastases? 12) Which specific drugs can be used for 
the patient with bone metastases?
these questions have been extensively discussed during a 
meeting organised in april 2006 in Brussels in Belgium. the 
present consensus has been definitively approved by the Group 
in a final meeting in Ostende, in October 2006.
M E T H O D O L O G y
Guidelines were established on the basis of the various data 
published in the literature: clinical trials, systematic reviews 
and meta-analyses, guidelines from medical societies or groups. 
Literature was identified and analysed by the evidence-based 
medicine group of the ELCWP. the quality of published 
guidelines was assessed with the use of the aGrEE instrument 
[3;4], allowing elimination of the worst ones and use of the best 
available ones for the establishment of our own guidelines. the 
following guidelines were selected: asCO (american society 
of Clinical Oncology) [5;6], Bts (British thoracic society) [7], 
Cancer Care Ontario Practice Guidelines [8], royal College 
of radiologists [9], american College of Chest Physicians 
(aCCP) [10] and FnCLCC (Fιdιration nationale des Centres 
de Lutte contre le Cancer) [11]. selection was based on the 
assessment of the literature previously performed by the aCCP 
[12] and it was completed by the analysis using the aGrEE 
instrument of other guidelines that had not been taken into 
consideration by the aCCP. this approach allowed adding to 
the list the guidelines of FnCLCC and aCCP.
Q U E S T I O N  1 :  w H A T  B E N E F I T S  C A N  B E 
E X P E C T E D  F R O M  C H E M O T H E R A P y  A N D  w H A T 
A R E  T H E  T R E A T M E N T  O B J E C T I V E S ?
randomised trials have shown benefits in terms of pallia-
tion, improvement of survival, symptom control, quality of live 
and costs. table 1 summarises the twelve trials that assessed 
the effect of combination chemotherapy (cisplatin-based in 
all but one) versus supportive care alone [13-25]. One study 
TABLE 1. randomised trials assessing combination chemotherapy plus supportive care versus supportive care alone in 
advanced nsCLC.
Reference Chemotherapy regimen Treatment Control p
n pts
(% St IV)
MS
(wk)
n pts
(% St IV)
MS
(wk)
Cormier, 1982 [13] MtX-adr-CPa-CCnu 20 (50) 30 19 (47) 8 s
rapp, 1988 [14] i. CddP-adr-CPa
ii. CddP-Vds
43 (86)
44 (82)
25
33
50 (90) 17 s
Ganz, 1989 [15] CddP-VBL 31 (100) 13 32 (100) 20 ns
Woods, 1990 [16] CddP-Vds 97 (74) 27 91 (57) 17 ns
Kaasa, 1991 [17] CddP-VP16 44 (100) 36 43 (100) 24 ns
Quoix, 1991 [18] CddP-Vds 24 (100) 28 22 (100) 10 s
Cellerino, 1991 [19] CPa-epirubicine-CddP ~ MtX-VP16-CCnu 62 (60) 34 61 (57) 21 ns
Leung, 1992 [20] CddP-VP16+ radiotherapy 42 (0) 50 62 (0) 35 s
Cartei, 1993 [21] CddP-CPa-MMC 52 (100) 36 50 (100) 17 s
Helsing, 1998 [22] Carboplatine + VP16 22 (91) 29 26 (88) 11 s
thongprasert,
1999 [23]
i. CddP-epirubicine-ifo
ii. CddP- MMC- VBL
96 (?)
93 (?)
25
35
98 (?) 18 s
Cullen, 1999 [24] MMC-ifo-CddP 165 (?) 29 177 (?) 21 s
spiro, 2004 [25] cisplatin-based (MMC-ifo-CddP, MMC-Vds-
CddP, CddP-Vds, CddP-Vnr)
364 (38) 32 361 (39) 23 s
MtX: methotrexate; adr: adriamycine; CPa: cyclophosphamide; CddP: cisplatin; Vds: vindιsine; VBL: vinblastine; MMC: mitomycin C; ifo: 
ifosfamide; Vnr: vinorelbine; st: stage: s: significant; ns: non significant; Ms: median survival; wk: week
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included only patients with stage iii nsCLC [20). two thirds 
of the trials showed statistically significant improvement 
of survival. in addition, four trials (table 2) have compared 
single agent chemotherapy, using one of the newer drugs with 
best supportive care alone [26-29]. all but one [28] showed a 
significant survival improvement with chemotherapy.
Five meta-analyses [30-34], published in the nineties and 
including one performed with individual patients data [33], have 
confirmed a modest but significant effect with chemotherapy 
in terms of survival (ttable 3). symptoms control has been 
also demonstrated as summarised in the aCCP guidelines 
[35], with a high rate of improvement for cough, haemoptysis, 
pain, dyspnoea, weight less, anorexia and malaise. Quality of 
life has been assessed in 8 trials, with significant improvement 
in all but one (table 4). Finally, in term of costs, Canadian 
authors have shown, in the nCi-C trial [14], a reduced cost 
when chemotherapy is prescribed compared with supportive 
care alone [36].
the published guidelines recommend treatment with 
chemotherapy. More specifically, the royal College of ra-
diologists recommends cisplatin-based combinations in pa-
tients with performance status (Ps) 0-2 but in the context of 
a clinical trial; the FnCLCC recommends cisplatin-based 
chemotherapy for patients with Ps 0-1 [37]; the Cancer Care 
Ontario Program recommends cisplatin-based chemotherapy 
after a full discussion of benefit limitations and toxicity [8]; 
asCO recommends two-drug combination regimens in patients 
with good Ps (0, 1 and possibly 2) [6]; aCCP recommends 
platinum-based chemotherapy regimens for patients with Ps 
0, 1 and possibly 2 [35].
E L C w P  G U I D E L I N E S :
Chemotherapy is recommended in patients with good 
Ps. therapeutic objectives are survival and quality of life 
improvement and symptom control. Cisplatin-based chemo-
therapy with one of the regimens shown to be effective should 
be preferred. Carboplatin may be substituted for cisplatin if 
medical contraindications do exist. single agent chemotherapy 
with a drug shown to be effective compared with supportive 
care, may be considered in patients with poor Ps, and the 
choice among the active ones depends on the medical condi-
tion of the patient.
TABLE 2. randomised trials assessing single new drug chemotherapy plus supportive care versus supportive care alone 
in advanced nsCLC
Reference Treatment arm n pts
(% stage IV)
OR Survival
MS 1 yr p
italian Elderly,
1999 [26]
1. Vnr
2. -
76 (74)
78 (72)
20%
-
28 w
21w
32%
14%
0.03
ranson,
2000 [27]
1. PaC
2. -
79 (51)
78 (54)
16%
-
6.8 m
4.8 m
0.037
anderson,
2000 [28]
1. GEM
2. -
150 (41)
150 (39)
18%
-
5.7 m
5.9 m
25%
22%
0.84
roszkowski,
2000 [29]
1. dOC
2. -
137 (44)
70 (53)
13%
-
6 m
5.7 m
25%
16%
0.026
Vnr: vinorelbine; PaC: paclitaxel; GEM: gemcitabine; dOC: docetaxel; Ms: median survival; w: week; m: month;yr: year; Or: objective response; 
pts: patients.
TABLE 3. Meta-analyses assessing the effect of combination chemotherapy versus supportive care in advanced 
nsCLC
Reference Methodology Outcome criteria Trials number Patients number Result 
souquet, 1993 [30] iMa survival at 3, 6, 9, 12 et 18 months 7 706 s
Grilli, 1993 [31] iMa Mortality risk 6 635 s
Marino, 1994 [32] MaLsr Mortality risk 8 712 s
Collaborative Group, 1995 [33] idMa Overall survival 11 2334 s
sculier, 1999 [34] MaLsr Mortality risk 6 557 s
iMa: isolated meta-analysis of the literature; MadLsr: meta-analysis with systematic review of the literature; idMa: meta-analysis based on 
individual patients data; s: significant
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Q U E S T I O N  2 :  w H A T  A R E  T H E  A C T I V E 
C H E M O T H E R A P E U T I C  D R U G S  F O R  w H I C H 
E F F I C A C y  H A S  B E E N  S H O w N ?
the drugs used in the published trials can be divided in 
three groups: inactive (also called first-generation), old (sec-
ond-generation) and new (or modern or third-generation) ones. 
the second-generation group of drugs has been the topic of 
a meta-analysis performed by our Group [38]. they include 
cisplatin, ifosfamide, mitomycin C, vindesine, vinblastine. Each 
of these drugs is able to significantly improve the response 
rate of the disease. the third-generation of active drugs has 
also been the subject of a systematic review performed by our 
Group [39]. they include gemcitabine, paclitaxel, docetaxel 
and vinorelbine, all available in Europe. in the randomised 
trials summarised in table 2, all these drugs, excepting gem-
citabine, have been shown to improve survival in comparison 
to supportive care alone.
E L C w P  G U I D E L I N E S :
Chemotherapy regimens should include available active 
drugs. Old active (second-generation) drugs are cisplatin, 
ifosfamide, mitomycin C, vindesine and vinblastine. new 
active (third-generation) drugs are gemcitabine, paclitaxel, 
docetaxel and vinorelbine.
Q U E S T I O N  3 :  w H I C H  A R E  T H E  M O S T 
E F F E C T I V E  P L A T I N U M - B A S E D  R E G I M E N S  F O R 
F I R S T  L I N E  C H E M O T H E R A P y  ?
Many cisplatin-based regimens are commonly used, com-
bining cisplatin with old drugs such as vindesine, mitomycin C 
and/or ifosfamide or new drugs such as gemcitabine, docetaxel, 
paclitaxel or vinorelbine. Our recommendation is based on 
the following data. in their guidelines, the Ontario Program 
[8] and the FnCLCC [37] recommend cisplatin-containing 
chemotherapy, without further precision of the drug(s) to be 
combined. For the aCCP, chemotherapy should be platinum-
based with a new single agent [35]. For asCO, it should be a 
two-drug combination regimen [6]; non-platinum containing 
chemotherapy may be used as an alternative to platinum-based 
regimen. in patients with poor performance status, asCO 
recommends single-agent chemotherapy.
two types of meta-analyses are available [40]. in the 
first type (table 5), the trials are compared according to the 
number of drugs in the regimen. Polychemotherapy is associ-
ated with better results than single agent treatment [41;42]. 
two-drugs regimens are superior to one-drug regimen, both 
in terms of response and survival; three-drugs combinations 
are better to two-drugs only in terms of response [43]. in the 
second type (table 6), the role of specific drugs is analysed. 
TABLE 4. assessment of the effect of chemotherapy on 
quality of life in the trials comparing chemotherapy with 
supportive care alone in advanced nsCLC.
Reference Chemotherapy regimen survival QOL
rapp,
1988 [14]
i. CddP-adr-CPa
ii. CddP-Vds
s s
E l d e r l y 
Group,
1999 [26]
vinorelbine s s
thongprasert,
1999 [23]
i. CddP-epirubicine-ifo
ii. CddP- MMC- VBL
s s
Cullen,
1999 [24]
MMC-ifo-CddP s s
spiro,
2004 [25]
cisplatin-based (MMC-ifo-
CddP, MMC-Vds-CddP, 
CddP-Vds, CddP-Vnr)
s ns
ranson,
2000 [27]
Paclitaxel s s
anderson,
2000 [28]
Gemcitabine ns s
roszkowski
2000 [29]
docetaxel s s
adr: adriamycine; CPa: cyclophosphamide; CddP: cisplatin; Vds: 
vindesine; VBL: vinblastine; MMC: mitomycin C; ifo: ifosfamide; Vnr: 
vinorelbine; s: significant; ns: non significant; QOL: quality of life
TABLE 5. Meta-analyses assessing the number of drugs needed in chemotherapy regimens for advanced nsCLC
Reference Methodology Outcome criteria Trials number Patients number Result 
Single agent versus polychemotherapy
Marino, 1995 [41] MALSR Mortality risk 9 1493 S
Lilenbaum, 1998 [42] IMA Survival at 6 & 12 months 25 5156 S
One versus two drugs
Delbaldo, 2004 [43] IMA Median survival 30 6022 S
Two versus three drugs
Delbaldo, 2004 [43] IMA Median survival 30 4550 NS
iMa: isolated meta-analysis of the literature; MadLsr: meta-analysis with systematic review of the literature; idMa: meta-analysis based on 
individual patients data; s: significant; ns: non significant
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addition of a drug to a platinum derivative is beneficial in 
terms of survival [44) but not the addition of mitomycin-C to 
a basic chemotherapy regimen [45]. Gemcitabine appears to 
be associated with better outcome in a meta-analysis of the 
literature but with much heterogeneity among the aggregated 
trials [46]. the combination of cisplatin with docetaxel does 
not appear to result in better survival in comparison to other 
cisplatin-based regimens [47]. in practice guidelines about the 
use of taxanes, in 2005, the Canadians recommend paclitaxel 
or docetaxel plus cisplatin as one of a number of chemotherapy 
options in patients with good performance status [48].
there are very few randomised trials having directly 
comparing cisplatin-based regimens combining new versus 
old drugs. Practically, cisplatin plus gemcitabine was better 
than cisplatin + ifosfamide + mitomycin-C in terms only of 
response but not of survival [49]. Cisplatin + vinorelbine was 
not superior to cisplatin + vindesine + mitomycin-C [50]. Cis-
platin + carboplatin + gemcitabine was not better than the old 
combination with ifosfamide [51]. a Japanese trial compared 
cisplatin-irinotecan to cisplatin-vindesine, without finding 
a difference [52]. in another Japanese study, cisplatin plus 
docetaxel was shown to be better than cisplatin plus vindesine 
for both responses and survival [53] while a British trial, using 
carboplatin + docetaxel, failed to show better outcome than 
with the old combination MVP or MiP [54]. it should be noted 
that, in the early nineties, an italian trial had shown survival 
advantage with these two latter regimens in comparison to 
the cisplatin plus etoposide combination [55].
E L C w P  G U I D E L I N E S :
Chemotherapeutic regimens should include cisplatin with 
at least one other active drug. if the other drug is a new one, 
there is no evidence for the addition of a third agent outside 
the context of a clinical trial. there is also no evidence that 
combinations with new drugs are superior to those with old 
drugs in terms of survival. Cost of the treatment including sup-
portive care and complications management has to be taken 
into consideration in the choice of the regimen.
Q U E S T I O N  4 :  w H I C H  I S  T H E  I N D I C A T E D 
D O S A G E  O F  C I S P L A T I N ?
this question has not been addressed in available guide-
lines. there are five randomised trials on that question (table 
7), all performed with old drugs [56-60]. none was able to 
report a significant advantage in favour of high dosages of 
cisplatin (100-120 mg/m2) in comparison to lower dosages 
(50-60 mg/m2). in fact, the use of high dose cisplatin is based 
on the observation of Gralla [56] that responders to cisplatin 
plus vindesine survived longer when 120 mg/m2 of cisplatin 
was administered instead of 60 mg/m2. this difference was 
observed in a very small group of patients (35 patients) and 
our Group was unable to replicate the results in a much 
higher number of patients [57]. High-dosage of cisplatin has 
the disadvantage of significantly higher renal, auditory and 
neurologic toxicities [61].
E L C w P  G U I D E L I N E S :
there is no demonstration that high doses of cisplatin (100-
120 mg/m2) provide better results than standard lower doses 
(50-60 mg/m2) in terms of survival. standard doses are associ-
ated with reduced toxicity and are thus recommended.
Q U E S T I O N  5 :  C A N  C A R B O P L A T I N  B E 
S U B S T I T U T E D  F O R  C I S P L A T I N ?
the FnCLCC guidelines [37] and the Cancer Care Ontario 
Program recommend cisplatin-based chemotherapy while 
the american societies aCCP [35] and asCO [6] propose 
platinum-based chemotherapy, using interchangeably cisplatin 
and carboplatin.
the level of evidence is based on ten published randomised 
trials [62-71] summarised in table 8 and one meta-analysis 
of the literature [72]. in randomised trials, the trend is in 
favour of cisplatin, both in terms of response and survival. 
the meta-analysis confirms this impression; the results are 
statistically significant in favour of cisplatin if the analysis is 
restricted to the regimens using new drugs combined with 
platinum derivatives.
TABLE 6. Meta-analyses assessing the role of particular drugs for chemotherapy in advanced nsCLC.
Reference Methodology Outcome N trials N patients Result
Addition of a drug to a platinum derivative
Hotta, 2004 [44] MaLsr survival 8 2374 s
Addition of mitomycin to a basic chemotherapy regimen
sculier, 2001 [130] srL with Ma Overall survival 10 1769 ns
Role of chemotherapy with gemcitabine in comparison to other drugs
Le Chevalier, 2005 [46] iMa survival 13 4556 s
Cisplatin + docetaxel versus other associations with cisplatin
sanchez Lerma, 2004 [47] iMa Overall survival 3 1980 ns
iMa: isolated meta-analysis of the literature; MadLsr: meta-analysis with systematic review of the literature; s: significant; ns: non significant
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TABLE 7. randomised trials assessing the role of the dosage of cisplatin
Reference Regimen n (st IV) % OR p MST p
Gralla, 1981 i. CddP (120 mg/m2) +Vds 41 40 ns ns
ii. CddP (60 mg/m2) +Vds 40  46  
Klastersky, 1986 CddP-VP16    ns  ns
i. 120 mg/m2 116 (63) 29 28 w
ii. 60 mg/m2 125 (76) 25 33 w
shinkai, 1986 i. CddP (120 mg/m2) +Vds 24 (19) 39 ns 9 m  
ii. CddP (80 mg/m2) +Vds 21 (16) 33 10.8 m
Gandara, 1993 CddP    ns  ns
i. 2 x 100 mg/m2 108 (108) 14 5.3 m
ii. 2 x 50 mg/m2 105 (105) 12 6.9 m
sculier, 2000 ifo – MMC    ns  ns
i.CddP 50 mg/m² 147 (143) 27 28 w
ii. CddP 60 mg/m² + CBdCa (200 mg/m²) 150 (145) 33 32 w
CddP: cisplatin; CBdCa: carboplatine; Vds: vindesine; MMC: mitomycin C; ifo: ifosfamide; ns: non significant; st: stage; Or: objective response; 
Mst: median survival time; w: week; m: month
TABLE 8. randomised trials comparing cisplatin-based with carboplatin-based regimens in advanced nsLC
Reference Chemotherapy n % OR p MST p
Klastersky, 1990 [62] i. CddP (120 mg/m2) + VP16 114 27 0.07 30 w ns
ii. CBdCa (325 mg/m2)+VP1 6 114 16 27 w
Comella, 1994 [63] i. CddP (60 mg/m2) + VP16+ epir. 28 62 ns ?
ii. CBdCa (300 mg/m2) + VP16 + epir. 30 59 ?
Jelic, 2001 [64] i. CddP (120 mg/m²) + MMC + Vds 112 36 ns 0.008
ii. CBdCa (500 mg/m²) + MMC + Vds 107 30
schiller, 2002 [65] i.CddP (75 mg/m²) + Paclitaxel (135 mg/m²) 303 21 ns 7.8 m ns
ii.Carbo (auC 6) + Paclitaxel (225 mg/m²) 299 17 8.1 m
rosell, 2002 [66] i.CddP (80 mg/m²) + Paclitaxel (200 mg/m²) 309 27 ns 9.8 m 0.02
ii. CBdCa (auC 6) + Paclitaxel (200 mg/m²) 309 24 8.2 m
Mazzanti, 2003 [67] i. CddP (80 mg/m²) + gemcitabine 62 42 ns 10 m ns
ii. Carboplatine (auC 5) + gemcitabine 58 31 10.8 m
Fossella, 2003 [68] i. docetaxel + CddP (75) 408 32 s 11.3 m 0.044
ii. docetaxel + Carboplatine (auC 6) 404 24 9.4 m
iii. CddP (100) + Vnr 404 24,5 10.1 m
Zatloukal, 2003 [69] i. CddP (80) + gemci 87 41 0.09 8.7 m 0.9
ii Carboplatin (auC 5) + gemci 89 29 8 m
Paccagnella, 2004 [70] i. CddP (100) + MMC + VBL 75 38 ns 7.2 m 0.19
ii. Carboplatine (300) + MMC + VBL 78 43 10 m
Chen, 2006 [71] i. Paclitaxel (160) + CddP (60) 41 30 ns 10.5 m
ii. Paclitaxel (160) + Carbo (auC 6) 40 40 10.3 m
CddP: cisplatin; CBdCa: carboplatine; Vds: vindesine; VBL: vinblastine; MMC: mitomycin C; ifo: ifosfamide; Vnr: vinorelbine; epir: epirubicine 
; ns: non significant; st: stage; Or: objective response; Mst: median survival time; w: week; m: month
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E L C w P  G U I D E L I N E S :
Cisplatin should be preferred to carboplatin because of 
a better effect on survival. Carboplatin or a non-platinum 
based regimenmay be prescribed if the patient is unable or 
unwilling to take cisplatin.
Q U E S T I O N  6 :  w H I C H  I S  T H E  O P T I M A L  N U M B E R 
O F  C y C L E S  T O  B E  A D M I N I S T E R E D ?
aCCP recommends short treatment with 3 to 4 cycles and 
asCO no more than 6 cycles, maximum of 4 if no response 
is observed [6]. Other scientific societies do not make recom-
mendations about chemotherapy duration.
in fact, the level of evidence is poor, based on a limited 
number of randomised trials shown in table 9 [73-76]. two 
studies compared 3 with 6 cycles [73;77] and another 4 cycles 
with treatment until disease progression [74]. the last two 
trials compared, after induction chemotherapy, maintenance 
treatment using paclitaxel [75] or vinorelbine [76] versus obser-
vation. in none, prolongation of chemotherapy demonstrated 
an advantage.
E L C w P  G U I D E L I N E S :
the optimal duration of chemotherapy in advanced nsCLC, 
is poorly defined. a minimum of 4 to 6 cycles is proposed in 
responding patients. Prolongation with single drug appears 
ineffective in terms of survival. the attitude of continuing 
treatment until best response merits further assessment.
Q U E S T I O N  7 :  C A N  N O N - P L A T I N U M 
B A S E D  R E G I M E N S  B E  S U B S T I T U T E D  F O R 
P L A T I N U M B A S E D  C H E M O T H E R A P y A S  F I R S T 
L I N E  T R E A T M E N T ?
asCO is the only scientific society recommending non-
platinum regimens as an alternative for platinum-based che-
motherapy as first-line treatment of patients with advanced 
nsCLC [6]. For all other societies, chemotherapy in that 
indication should be platinum-based.
randomised published trials [51;78-95] on the topic are 
summarised in table 10. in terms of survival, there is no statisti-
cally significant difference between the 2 types of treatment 
in all but one trial. Barlesi and Pujol [96] have performed in 
2005 a systematic review of the phase iii trials available in 
the literature. they concluded that the approach is still debat-
able when doublet-regimens with new drugs are considered. 
they did not report a meta-analysis. d’addario et al [97] have 
performed a meta-analysis of the published literature. When 
all trials were considered (irrespectively of using old or new 
drugs), there was a significant advantage both for response 
rate and 1-year survival in favour of platinum-based treatment. 
the increase in 1-year survival was 5%. When the analysis 
was restricted to combination regimens with new drugs, there 
was no significant difference in survival but response rate was 
significantly improved with platinum-based treatment.
E L C w P  G U I D E L I N E S :
non-platinum-based regimens as first-line treatment for 
TABLE 9. randomised trials assessing the duration of chemotherapy in advanced nsCLC.
Reference Regimen n (st IV) % OR p MST p
smith, 2001 [73] CddP (50 mg/m²) + MMC + VBL ns ns
i. 3 cycles 155 (72) 31 6 m
ii. 6 cycles 153 (81) 32 7 m
socinski, 2002 [74] Carbo (auC 6) + paclitaxel (200) ns ns
i. 4 cycles 114 (100) 22 6.6 m
ii until progression 116 (100) 24 8.5 m
Belani, 2003 [131] Carbo + paclitaxel 4 cycles: Cr/Pr/nC: ns
i. paclitaxel 70 mg/m²/wk 3 wk/4 66 72% 75 w
ii. observation 65 78% 60 w
Westeel, 2005 [76] response to MMC + ifo + CddP 573 ns
i. - 90 53% 12.3 m
ii Vnr 6 months 91 43% 12.3 m
Von Plessen, 2006 [77] Carbo + vinorelbine 
nsi. 3 cycles 150 (113) na 28 w
ii. 6 cycles 147 (113) na 32 w
CddP: cisplatin; Carbo: carboplatine; VBL: vinblastine; MMC: mitomycin C; ifo: ifosfamide; ns: non significant; st: stage; Or: objective response; 
Mst: median survival time; w: week; m: month; na: not available
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TABLE 10. randomised trials testing platinum-based regimens versus non-platinum-based regimens as primary 
chemotherapy for advanced nsCLC.
Reference Chemotherapy (dosage) n (st IV) % OR p MS p
Georgoulias,
2001 [78]
i. CddP (80 mg/m²)+docetaxel (100 mg/m²) 205 (129) 35
ns
10 m
nsii. Gemci + docetaxel (100 mg/m²) 201 (130) 33 9.5 m
sculier,
2002 [51]
i.CddP (50) + CBdCa (200) + ifo 94 all 23
ns
24 wk
nsii.CddP(50) + CBdCa (200) +Gemci 92 29 34 wk
iii.ifo + gemcitabine 94 25 30 wk
Kosmidis,
2002 [79]
i. Paclitaxel (200 mg/m²) + Carbo (auC 6) 252 (158) 28
0.12
10.4 m
0.32ii. Paclitaxel (200 mg/m²) + gemcitabine 257 (148) 35 9.8 m
Greco,
2002 [80]
i. CBdCa (auC 5)+paclitaxel (200)+ gemci 71 (51) 37
ns
9.2 m
nsii. CBdCa (auC 6)+paclitaxel (200)+ Vnr 65 (51) 45 8.6 m
iii. paclitaxel (200)+ gemci 64 (53) 32 8.7 m
iV. Gemci + Vnr 67 (49) 33 10.7 m
Chen,
2002 [81]
i. Carboplatine (auC 7) + paclitaxel (175) 45 40 14.1 m
ii. paclitaxel (175) + gemci 45 40 12.6 m
Gebbia,
2003 [82]
i. CddP + gemcitabine 138 (73) 34
0.007
8.2 m
nsii. CddP + vinorelbine 140 (75) 44 9.0 m
iii. ifo + gemcitabine then CddP + Vnr 60 (33) 19
iV. CddP + Vnr then ifo + gemcitabine 60 (31) 31
Gridelli,
2003 [83]
i. CddP (80) + Vnr 126 80%
30 ns 38 wk 0.08ii. CddP (80) + gemcitabine 126 81%
iii. Vnr + gemcitabine 251 80% 25 32 wk
alberola,
2003 [84]
i. CddP (100) + gemcitabine 182 77 % 42
s
9.3 m
nsii. CddP (100) + gemcitabine + Vnr 188 79 % 41 8.2 m
iii. gemci + Vnr x 3 then ifo + Vnr x 3 187 81 % 27 8.1 m
smit,
2003 [85]
i. paclitaxel (175) + CddP (80) 159 (130) 32
ns
8.1 m
nsii. CddP (80) + gemci 160 (126) 37 8.9 m
iii. paclitaxel (175) + gemci 161 (136) 28 6.7 m
Wachters,
2004 [86]
i. CddP + gemcitabine 119 57% 46% ns 43 wk 0.14
ii. Epirubicine + gemcitabine 121 57% 36% 36 wk
Yamamoto,
2004 [87]
i. CddP (80) + docetaxel (60) 51 (40) 37 % ns 50 wk ns
ii. irinotecan + docetaxel (60) 57 (43) 32 % 46wk
Laack,
2004 [88]
i. CddP (75 J2) + gemci + Vnr 144 (126) 28 % 0.004 32 wk 0.73
ii. gemci + Vnr 143 (125) 13 % 36 wk
stathopoulos,
2004 [89]
i. Paclitaxel (135) + vinorelbine 175 47% 43 % ns 10 m ns
ii. Paclitaxel (175) + carboplatine (auC 6) 185 49% 46 % 11 m
Lilenbaum,
2005 [90]
i. gemci + Vnr 82 82% 14,6 % 7.8 m
ii. Paclitaxel + carboplatine 83 81% 16,9% 8.6m
Chen,
2005 [91]
i. Vnr (20 d1,8,15) + gemci (800 d1,8,15) 43 77% 23 % 0.02 9.5 m ns
ii. idem + CddP (60 d15) 43 81% 46 % 13.1 m
Pujol,
2005 [92]
i. Gemcitabine + docιtaxel (85) 155 79 % 31 % ns 11.1 m ns
ii. CddP (100) + vinorelbine 156 86 % 36 % 9.6 m
Georgoulias,
2005 [93]
i. Vinorelbine (30 d1 & 8) + CddP (80 d8) 204 64% 39 % 0.053 8.6 m ns
ii. Gemcitabine (1 d1 & 8) + docetaxel (80 d8) 209 62% 30 % 9.0 m
tan,
2005 [132]
i. Gemcitabine + vinorelbine 157 80% 28 % 0.15 11.5 m 0.01
ii. Carboplatine (auC 5) + vinorelbine 159 90% 21 % 8.5 m
Katagami,
2006 [95]
i. docetaxel (60) + cisplatine (80) 68 73% 23% ns 11.4 m ns
ii. docetaxel (60) + gemcitabine 63 75% 27% 13.7 m
CddP: cisplatin; CBdCa: carboplatine; ifo: ifosfamide; Vnr: vinorelbine; st: stage: s: significant; ns: non significant; Or: objective response; 
Mst: median survival time; Ms: median survival; wk: week; d: day
ELCWP CLiniCaL PraCtiCE GuidELinEs. nsCLC: iii. MEtastatiC disEasE
177
advanced nsCLC, may be used in cases where platinum-based 
chemotherapy is contra-indicated. For all other patients, they 
should be used only in the context of clinical trials.
Q U E S T I O N  8 :  I S  T H E R E  A N  I N D I C A T I O N  F O R 
S E Q U E N T I A L  C H E M O T H E R A P y ?
there is only one randomised phase ii trial published 
on the topic [98]. the ELCWP has completed a large phase 
iii trial where patients without disease progression after 3 
courses of cisplatin-based chemotherapy were randomised 
between further platinum-based chemotherapy or paclitaxel 
with crossover at the time of progression. there was no differ-
ence in survival between the two approaches, the trend being 
in favour of the non-sequential approach.
E L C w P  G U I D E L I N E S :
there is no indication for sequential chemotherapy with 
taxanes (or other drugs) in the management of advanced 
nsCLC.
Q U E S T I O N  9 :  w H A T  I S  T H E  E F F I C A C y  O F 
S A LVA G E  C H E M O T H E R A P y  A N D  w H I C H  D R U G S  
S H O U L D  B E  U S E D  I N  T H A T  I N D I C A T I O N ?
second-line chemotherapy is recommended in the guide-
lines of aCCP and asCO. according to aCCP, it should be 
offered in patients with good Ps [35]. according to asCO, it 
should be consisted of docetaxel followed by gefitinib [6].
there is only one randomised trial having compared 
second-line chemotherapy with supportive care alone in ad-
vanced nsCLC. survival was significantly improved in the 
chemotherapy arm [99]. Other trials (table 11) have compared 
docetaxel to vinorelbine or ifosfamide [100], paclitaxel [101], 
pemetrexed [102] or oral topotecan [103]. none of the alternative 
approaches was shown to be better than docetaxel in terms of 
survival or response rate. some improvement was reported with 
pemetrexed in terms of tolerance. implementation studies have 
reported results similar to randomised trials when docetaxel 
was used in routine application [104;105]. Weekly administra-
tion of docetaxel has not been shown to be better [106-110] 
than three weekly treatment (table 12). a dosage of 75 mg/m² 
appears to be better tolerated than 100 mg/m² [111].
a systematic review of the literature concluded that second-
line chemotherapy produces a small but significant survival 
benefit [112].
E L C w P  G U I D E L I N E S :
second-line chemotherapy should be offered to patients 
with good performance status, failing platinum-based first-
line chemotherapy. Evidence is in favour of docetaxel (if not 
already administered as first-line treatment) given on a 3-weekly 
schedule at a dosage of 75 mg/m². additional controlled data 
are needed before substituting pemetrexed for docetaxel.
Q U E S T I O N  1 0 :  w H A T  I S  T H E  P L A C E  O F 
T A R G E T E D  T H E R A P I E S ?
EGF-r tyrosine kinase inhibitors (tKis), gefitinib and 
erlotinib, have been the subject of intensive clinical research 
during the last few years. Erlotinib is the first targeted drug 
commercially available in Europe for the management of 
nsCLC.
results were disappointing when tKis were used as first-
line therapy in association with chemotherapy. three large 
randomised trials were conducted, two with gefitinib by Gi-
accone and Herbst [113;114] and one with erlotinib by Herbst 
[115]. When they were also used as salvage therapy after che-
motherapy failure (table 13), tKis were shown to be superior 
to placebo, with a statistically significant survival advantage 
in the erlotinib trial [116]. the survival advantage was less 
TABLE 11. randomised trials testing salvage chemotherapy for nsCLC
Reference Chemotherapy n % OR p MST p
shepherd, 2000 [99] 1. dOC 104 6 7 m
0.047
2. BsC 100 - 4.6 m
Fossella, 2000 [100] 1. dOC 100 mg/m2 60 11
0.002 0.0252. dOC 75 mg/m2 59 7
3. Vnr ou ifo 60 1
Esteban, 2003 [101] 1. dOC26 mg/m²/wk 35 3
ns
105 d
ns
2. Paclitaxel 80 mg/m²/wk 36 14 184 d 
Hanna, 2004 [102] 1. Pemιtrexed 500 mg/m² 283 9
ns
8.3 m
ns
2. dOC 75 mg/m² 288 8 7.9 m
ramlau, 2006 [103] i. topotecan oral 2,3 mg/m² d1-5 414 5
ns
28 wk
0.057
ii. dOC 75 mg/m²/3 wk 415 5 31 wk
dOC: docetaxel; ifo: ifosfamide; Vnr: vinorelbine; st: stage; ns: non significant; Or: objective response; Mst: median survival time; Ms: median 
survival; wk: week ; d: day; m: month
178
HOsPitaL CHrOniCLEs 1(3), 2006
evident with gefitinib [117]. response rates were low (less than 
10%) but some initial characteristics of the patients or of the 
disease (female gender, asian ethnic origin, adenocarcinoma, 
no smoking history) were associated with significantly better 
response rates. some biological characteristics of the tumour 
were also associated with better outcome. EGF-r-positive 
immunohistochemisty and EGF-r amplification detected by 
FisH were positively associated with response and survival 
in erlotinib treatment patients [118]. Mutant EGF-r was 
not significantly associated with response but these data are 
controversial due to technical problems [119;120]. For gefi-
tinib, EGF-r gene mutation is associated with much higher 
response rates [121]. recent data were presented in the last 
asCO meeting (atlanta, 2006), as shown in table 14. When 
tKis were given in chemotherapy-naive patients whose tumour 
demonstrated EGF-r gene mutations, the response rate was 
very high (around 70 to 80%). a Japanese recent publication 
reports a rate of 75% [122]. Controlled trials are necessary to 
determine if tKis could replace chemotherapy in this type 
of patients.
E L C w P  G U I D E L I N E S :
EGF-r tyrosine kinase inhibitors should not be used as 
initial treatment of patients with advanced nsCLC. Erlotinib 
can be used as salvage treatment in patients whose tumour 
shows abnormal expression of EGF-r. target identification 
on the tumour merits further investigations.
Q U E S T I O N  1 1 :  w H A T  I S  T H E  P L A C E  O F 
C H E M O T H E R A P y  I N  T H E  M A N A G E M E N T  O F  A 
PA T I E N T  w I T H  B R A I N  M E T A S T A S E S ?
Brain metastases is usually treated by non systemic treat-
ment such as surgery, whole-brain irradiation and, more re-
cently, stereotactic radiosurgery. in the ELCWP experience, 
the presence of brain metastases in stage iV nsCLC patients 
treated with chemotherapy, is not an adverse prognostic factor 
in terms of survival or response [123-125].
there is only one controlled trial published concerning 
timing of brain irradiation in minimally symptomatic patients. 
the problem was if brain irradiation has to be administered 
early or can be delayed while systemic chemotherapy is delivered 
[126]. a total of 176 patients with nsCLC and inoperable brain 
metastases, treated by 6 cycles of cisplatin plus vinorelbine, 
were randomised between early brain irradiation (during 
cycle 1) or delayed brain irradiation (when no response of 
brain metastases to chemotherapy or after chemotherapy). 
there was no difference between the two approaches in terms 
of extracranial response rate, intracranial response rate or 
TABLE 12. randomised trials testing weekly versus 3 weekly docetaxel as salvage chemotherapy for advanced nsCLC
Reference Chemotherapy n % OR p MST p
Gervais, 2005 [106] 1. docetaxel 75 mg/m²/3 wk 62 4.8 5.8 m
2. docetaxel 40 mg/m²/ wk 63 3.2 5.6 m
Gridelli, 2004 [107] 1. docetaxel 75 mg/m²/3 wk 110
ns
29 wk
ns
2. docetaxel 33.3 mg/m²/wk 110 25 wk
schuette, 2005 [108] i. docetaxel 75 mg/m²/3 wk 103 12.6
ns
6.3 m
0.07
ii. docetaxel 35 mg/m²/wk 105 10.5 9.2 m
Camps, 2006 [109] i. docetaxel 75 mg/m²/3 wk 131 9.3
ns
6.6 m
0.07
ii. docetaxel 36 mg/m²/wk 128 4.8 5.4 m
Chen, 2006 [110] i. docetaxel 35 mg/m² d1,8,15 every 4 wk 64 17.2
ns
8.4 m
nsii. docιtaxel 40 mg/m² d1 & 8 every 3 wk 64 10.9 7.2 m
iii. docιtaxel 75 mg/m²/3 wk 33 6.1 9.5 m
ns: non significant; Or: objective response; Mst: median survival time; Ms: median survival; wk: week ; d: day; m: month
TABLE 13. randomised trials assessing tyrosine kinase inhibitors as salvage treatment for nsCLC
Reference Regimen N OR p MST p
sheperd, 2005 [116] i. erlotinib 150 mg/d 488 8.9
s
6.7 m
<0.001
ii. placebo 243 1 4.7 m
thatcher, 2005 [117] i. gefitinib 250 mg/d 1129 8 5.6 m
0.087
ii. placebo 563 5.1 m
Or: objective response; Mst: median survival time; Mst: median survival time; d: day; m: month
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overall survival.
ELCWP GUIDELINES:
Minimally symptomatic patients with brain metastases 
should receive systemic chemotherapy. Brain irradiation can 
be safely delayed until the completion of chemotherapy or 
when no response of brain metastases to chemotherapy is 
documented.
Q U E S T I O N  1 2 :  w H I C H  S P E C I F I C  D R U G S  
C A N  B E  U S E D  F O R  T H E  PA T I E N T  w I T H  B O N E 
M E T A S T A S E S ?
Bone metastases can be treated when necessary, by local 
treatment including irradiation, surgery or cimentoplasty or 
by systemic chemotherapy. the question arises if the addition 
of bisphosphonates in the patient with nsCLC and metastatic 
bone lesions is a useful approach.
there is no specific trial testing bisphosphonates in nsCLC. 
a randomised study has been performed with zoledronic acid in 
patients with solid tumours [127;128]. there were significantly 
less skeletal-related events with zoledronic acid in comparison 
to placebo. in a subgroup analysis for lung cancer patients, 
the skeletal-related events were significantly reduced but, if 
hypercalcaemia was not taken into consideration, the effect 
was only marginal. it should be noted that late complications 
of bisphosphonates administration (mandibular necrosis) have 
been recently reported [129].
E L C w P  G U I D E L I N E S :
Bisphosphonates are a therapeutic option in patients with 
uncontrolled bone metastases despite adequate local treatment 
and systemic chemotherapy. the risk of mandibular necrosis 
has to be taken in consideration.
C O N C L U S I O N S
the ELCWP guidelines can be summarised as follows :
1. Chemotherapy is recommended in patients with good 
Ps. treatment objectives are survival, quality of life and 
symptom control improvement.
2. Chemotherapy regimens should include active drugs. 
active old (second-generation) drugs are cisplatin, ifos-
famide, mitomycin C, vindesine and vinblastine. active 
new (third-generation) drugs are gemcitabine, paclitaxel, 
docetaxel and vinorelbine.
3. Cisplatin-based chemotherapy with one of the effective 
regimens should be used. if the second drug is a new one, 
there is no evidence for the addition of a third agent outside 
the context of a clinical trial. there is also no evidence 
that combinations with new drugs are superior to those 
with old drugs in term of survival.
4. there is no conclusive evidence that high doses of cispla-
tin (100-120 mg/m2) provide better results than standard 
lower doses (50-60 mg/m2) in terms of survival. standard 
doses are associated with reduced toxicity and are thus 
recommended.
5. Cisplatin should be the preferred drug compared to carbo-
platin because of a better survival outcome. Carboplatin 
may be prescribed if the patient is unable or unwilling to 
receive cisplatin.
6. the optimal duration of chemotherapy is poorly documented 
in advanced nsCLC. a minimum of 4 to 6 cycles is advised 
in responding patients. Prolongation of treatment by single 
drug appears ineffective in term of survival.
7. non-platinum-based regimens are indicated as first-line 
treatment for advanced nsCLC in patients for whom 
platinum-based chemotherapy is contra-indicated. single 
drug chemotherapy may be considered in patients with 
poor Ps. the choice of the active drugs depends on the 
patient’s medical condition.
8. there is no indication for sequential chemotherapy with 
taxanes (or other drugs) in the management of advanced 
nsCLC.
9. second-line chemotherapy should be offered in patients 
with good performance status, failing on or after plati-
num-based first-line chemotherapy. Evidence is in favour 
TABLE 14. Effects of tyrosine kinase inhibitors (tKi) in patients with mutations of the EGFr gene: prospective trials 
(excepting one) presented at asCO 2006
Author Screened Mutations TKI N pts RR PFS OS
Paz-ares (# 7020) 1047 18.7% erlotinib 43 82% 5Cr 13 m 82% (1 yr)
Okamoto (# 7073) 104 27% gefitinib 25 75%
takano (# 7075)
retrospective
207 41% gefitinib 86 78% 9.2 m 20 m
sutani (# 7076) 100 38% gefitinib 38 78% 9.4 m 15 m
Morikawa (# 7077) 123 37% gefitinib 46 69% 9.7 m
richard (# 7184) 111 17% gefitinib or erlotinib 7 57%
Pts: patients; rr: response rate; PFs: progression-free survival; Os: overall survival; m: month; yr: year
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of docetaxel (if not administered as first-line treatment) 
given on a 3-weekly schedule at a dosage of 75 mg/m².
10. EGFr tyrosine kinase inhibitors should not be used as 
initial treatment of patients with advanced nsCLC. Er-
lotinib can be used as salvage treatment in patients whose 
tumour shows abnormal expression of EGFr.
11. Minimally symptomatic patients with brain metastases 
should receive systemic chemotherapy. Brain irradiation 
can be safely delayed until the completion of chemotherapy 
or be given when no response of brain metastases to che-
motherapy is documented.
12. Bisphosphonates is a therapeutic option in patients with 
uncontrolled bone metastases despite adequate local treat-
ment and systemic chemotherapy. the risk of mandibular 
necrosis has to be taken in consideration.
13. Cost of the treatment including supportive care and com-
plications management has to be taken into consideration 
in the choice of the regimen.
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